Seminars in breast disease最新文献_第7页

The Current Paradigm for Breast Irradiation: The Case for Treating the Whole Breast over Six Weeks 当前乳房放射治疗的范例:治疗整个乳房超过6周的案例

Seminars in breast disease Pub Date : 2007-03-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.04.001

Janice N. Kim MD , Waylene Wang MD , Benjamin O. Anderson MD

引用次数: 0

Lumpectomy and Partial Breast Irradiation as an Alternative to Mastectomy After Prior Breast Irradiation 乳房肿瘤切除术和部分乳房放疗作为先前乳房放疗后乳房切除术的替代选择

Seminars in breast disease Pub Date : 2007-03-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.04.005

Jarrod B. Adkison MD , Rakesh R. Patel MD , Robert R. Kuske MD

{"title":"Lumpectomy and Partial Breast Irradiation as an Alternative to Mastectomy After Prior Breast Irradiation","authors":"Jarrod B. Adkison MD , Rakesh R. Patel MD , Robert R. Kuske MD","doi":"10.1053/j.sembd.2007.04.005","DOIUrl":"10.1053/j.sembd.2007.04.005","url":null,"abstract":"<div>Mastectomy has long been regarded as the standard of care for local relapse after breast-conserving surgery and radiation therapy. Due to the perceived heightened risk of toxicity, a similar rationale and approach is often employed for patients that develop a new breast cancer after being treated with mantle field irradiation for Hodgkin’s disease or lymphoma. Patients are increasingly requesting additional breast conserving treatment following an initial excellent cosmetic outcome before recurrence. After receiving whole breast external beam radiation therapy, most recurrences occur within or close to the quadrant of the index lesion. Partial breast irradiation (PBI) can target the areas at greatest risk for residual microscopic disease while minimizing the volume of healthy breast tissue re-irradiated. Studies with short follow up suggest that catheter-based interstitial brachytherapy or limited-field external beam radiotherapy can be safely delivered to the breast following an initial course of external bream radiotherapy with acceptable outcomes. A prospective, randomized Phase II multicenter trial to evaluate repeat lumpectomy followed by PBI for in-breast tumor recurrence is warranted to explore the role of repeat breast-conservation.</div>","PeriodicalId":87785,"journal":{"name":"Seminars in breast disease","volume":"10 1","pages":"Pages 37-41"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1053/j.sembd.2007.04.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"57941450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative Approaches to Accelerated Partial Breast Irradiation 加速乳房部分照射的创新方法

Seminars in breast disease Pub Date : 2007-03-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.08.004

C. Wesley Hodge MD , Rakesh R. Patel MD , Salih Gurdalli PhD , Robert R. Kuske MD

{"title":"Innovative Approaches to Accelerated Partial Breast Irradiation","authors":"C. Wesley Hodge MD , Rakesh R. Patel MD , Salih Gurdalli PhD , Robert R. Kuske MD","doi":"10.1053/j.sembd.2007.08.004","DOIUrl":"10.1053/j.sembd.2007.08.004","url":null,"abstract":"<div>Early outcomes from studies evaluating accelerated partial breast irradiation (APBI) as an alternative adjuvant treatment after breast-conserving surgery for early-stage breast cancer have been promising. The method with the longest-standing history and supporting outcome data for APBI is multi-catheter interstitial brachytherapy. The advent of a single-channel intracavitary device, Mammosite balloon, has allowed a more simple and reproducible approach and in turn has led to an increased number of patients treated with APBI. More recently, several investigators have explored emulating the brachytherapy methods with a noninvasive external beam approach. Currently, a large phase III clinical trial is evaluating these three APBI approaches with the conventional fractionated whole breast radiation course. Based on the favorable outcomes of the above techniques, there have been several innovative methods of APBI that have been developed in an effort to bridge the benefits and overcome certain limitations inherent in existing techniques. These novel approaches will be reviewed, and a summary of the advantages, disadvantages, and phase of clinical development will be provided.</div>","PeriodicalId":87785,"journal":{"name":"Seminars in breast disease","volume":"10 1","pages":"Pages 50-56"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1053/j.sembd.2007.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"57941753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guest Editorial: The Politics of Change in Medicine 客座评论:医学变革的政治

Seminars in breast disease Pub Date : 2007-03-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.08.003

Robert R. Kuske MD (Guest Editor)

引用次数: 1

Staging and Restaging of Breast Cancer Using FDG-PET and PET/CT FDG-PET和PET/CT对乳腺癌分期和再分期的影响

Seminars in breast disease Pub Date : 2006-12-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.02.004

Bara Mouradi MD , William C. Lavely MD , Paul Lizotte DO

引用次数: 0

Cardiac Evaluation, Toxicity and Monitoring in the Treatment of Breast Cancer 乳腺癌治疗中的心脏评价、毒性和监测

Seminars in breast disease Pub Date : 2006-12-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.02.006

Curtiss T. Stinis MD , Mohammad-Reza Movahed MD, PhD, FACP, FACC, FSCAI, FCCP

{"title":"Cardiac Evaluation, Toxicity and Monitoring in the Treatment of Breast Cancer","authors":"Curtiss T. Stinis MD , Mohammad-Reza Movahed MD, PhD, FACP, FACC, FSCAI, FCCP","doi":"10.1053/j.sembd.2007.02.006","DOIUrl":"10.1053/j.sembd.2007.02.006","url":null,"abstract":"<div>Multiple chemotherapeutic drugs are used in the treatment of breast cancer, many of which have the potential to produce cardiotoxicity. The anthracyclines are highly efficacious against breast cancer, but pose a particularly high risk for cardiotoxicity. The incidence of anthracycline-induced cardiomyopathy increases in a dose-related fashion and with prior cardiac radiation exposure. The exact mechanism of toxicity is unknown, but the maximum tolerated cumulative dose can be increased by reducing peak drug levels and with concurrent administration of dexrazoxane. Because anthracycline-induced cardiomyopathy is largely irreversible and cumulative, prevention is the preferred strategy. Monitoring by assessment of left ventricular function by the most reproducible method available as patients approach potentially toxic doses can substantially reduce toxicity. The long-term outcome of anthracycline-induced cardiomyopathy is better than previously reported because of advances in therapy. Recommendations for cardiac monitoring depend on the baseline cardiac function. In patients with baseline left ventricular ejection fraction (LVEF) >50%, periodic assessment of LV function will depend on other cardiac risk factors present and cumulative dosing of the cardiotoxic drugs. A decrease in LVEF of more than 10% or an absolute decrease to less than 30% is an indication for doxorubin discontinuation. Doxorubin-based chemotherapy should not be initiated in patients with a baseline LVEF of less than 30%.</div>","PeriodicalId":87785,"journal":{"name":"Seminars in breast disease","volume":"9 4","pages":"Pages 160-167"},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1053/j.sembd.2007.02.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"57941144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Roles of Skeletal Scintigraphy and FDG PET in Evaluation of Bone Metastases in Breast Cancer 骨显像和FDG PET在乳腺癌骨转移评估中的作用

Seminars in breast disease Pub Date : 2006-12-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.02.001

Mohammad Helmy, Imelda Y. Ho, Paul Lizotte

引用次数: 1

The Use of Positron Emission Tomography in Response to Therapy 正电子发射断层扫描在治疗反应中的应用

Seminars in breast disease Pub Date : 2006-12-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.02.005

Kimberly Ray MD, Paul Lizotte DO, FACP, FACE

引用次数: 0

PET Imaging of Breast Cancer: Beyond Standard FDG Studies 乳腺癌的PET成像:超出标准FDG研究

Seminars in breast disease Pub Date : 2006-12-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.02.007

Jean H. Lee MD, Lavanya Sundararajan MD, William B. Eubank MD, David A. Mankoff MD, PhD

引用次数: 0

Sentinel Lymph Node Update 前哨淋巴结更新

Seminars in breast disease Pub Date : 2006-12-01 Epub Date: 2008-09-25 DOI: 10.1053/j.sembd.2007.02.003

Francesca Hoehne MD, Helen Mabry MD, Armando E. Giuliano MD, FACS

引用次数: 0